Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, Roshon M, Wrzesinski SH, Desai JV, Zarakas MA, Collen J, Rose K, Hamdy A, Izumi R, Wright GW, Chung KK, Baselga J, Staudt LM, Wilson WH. · 2020

Read Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. by Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, Roshon M, Wrzesinski SH, Desai JV, Zarakas MA, Collen J, Rose K, Hamdy A, Izumi R, Wright GW, Chung KK, Baselga J, Staudt LM, Wilson WH. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7274761.txt.

Introduction

Roschewski and co-authors test a cancer drug, acalabrutinib, in patients with severe COVID-19. Their study appeared in Science Immunology. Severe disease often worsens after initial improvement, pointing to an exaggerated immune response that damages the lungs. The drug blocks Bruton tyrosine kinase, a protein active in macrophages, the immune cells that drive much of this inflammation.

Patients given acalabrutinib showed reduced inflammation alongside clinical improvement. The drug targets activated BTK in macrophages, calming the hyperinflammatory state linked to respiratory failure. Because BTK blockers were already developed for blood cancers, they could be tried quickly in the pandemic. The authors present the results as early evidence that targeting innate immunity can help in severe COVID-19.

Catalog record

CREATORRoschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, Roshon M, Wrzesinski SH, Desai JV, Zarakas MA, Collen J, Rose K, Hamdy A, Izumi R, Wright GW, Chung KK, Baselga J, Staudt LM, Wilson WH.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7274761

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 By Mark Roschewski, Michail S. Lionakis, Jeff P. Sharman, Joseph Roswarski, Andre Goy, M. Andrew Monticelli, Michael Roshon, Stephen H. Wrzesinski, Jigar V. Desai, Marissa A. Zarakas, Jacob Collen, Keith Rose Published in: Science Immunology DOI: 10.1126/sciimmunol.abd0110 ABSTRACT Acalabrutinib targets activated BTK in macrophages and was associated with reduced inflammation and clinical improvement in COVID-19. INTRODUCTION Coronavirus 2019 (COVID-19) is a new pandemic disease caused by a single-stranded RNA zoonotic virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). The spectrum of COVID-19 ranges from a mild respiratory illness to a severe disease requiring hospitalization in up to a third of patients, with frequent progression to acute respiratory distress syndrome (ARDS) and a high mortality (2). It has been reported that COVID-19 patients can have a biphasic clinical course with deterioration following initial improvement, consistent with a delayed and exaggerated immune activation (2–4). A virus-induced hyperinflammatory response or “cytokine storm” (5) has been hypothesized to be a major pathogenic mechanism of ARDS in these patients through modulation of pulmonary macrophages, dendritic cells and/or neutrophils (6–10). Indeed, patients with COVID-19 have elevated blood levels of multiple inflammatory cytokines and chemokines (IL-1β, IL-6, IL-7, IL-8, IL-9, IL-10, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, and MIP-1α), and those requiring admittance to an intensive care unit have even higher levels of many of these (11, 12). The hyperinflammatory response in COVID-19 shares biological characteristics with macrophage activation syndrome, suggesting that targeting the innate immune system may be an effective strategy (13). We became aware of the role of Bruton tyrosine kinase (BTK) in human innate immune responses from our studies of the BTK inhibitor ibrutinib in lymphoma, in which some patients developed invasive aspergillosis during treatment (14). Moreover, we demonstrated that BTK-deficient mice are unable to control infection with this fungus, which is normally kept in check by monocytes/macrophages and neutrophils (14–16). While this is an uncommon complication, it raised the possibility that BTK inhibitors may modulate human inflammatory responses dominated by macrophages, as is the case in COVID-19 (17, 18) and in a mouse model of this infection (Fig. 1) (19). In macrophages, Toll-like receptors (TLRs) recognize single-stranded RNA from viruses such as SARS-CoV-2 and initiate signaling through BTK-dependent activation of NF-κB, triggering the production of multiple inflammatory cytokines and chemokines as well as phagocytosis (Fig. 1) (20–23). In addition, BTK plays a key role in the activation of the NLRP3 inflammasome, resulting in maturation and secretion of IL-1β (24–26). Moreover, in a mouse influenza model, BTK inhibition decreased inflammatory mediators and rescued mice from lethal acute lung injury, suggesting that it may mitigate virally-induced lung damage driven by excessive inflammation (27). [Figure: Model of BTK-dependent hyper-inflammation in severe COVID-19.Binding of SARS-CoV2 to ACE2 on respiratory epithelia initiates infection. Hypothetically, macrophages may participate in the COVID-19 inflammatory response by phagocytic uptake of viral particles or cellular debris containing viral single-stranded RNA (ssRNA). ssRNA can bind to TLR7 and TLR8, thereby recruiting and activating BTK and MYD88 (51, 52). Downstream of TLR engagement, BTK-dependent NF-κB activation results in the production of pro-inflammatory cytokines and chemokines (53), a “cytokine storm” that could increase the recruitment of monocytes/macrophages and neutrophils during the late phase of severe COVID-19 infection. BTK inhibitors such as acalabrutinib block TLR-dependent NF-κB activation in macrophages (20, 21), thereby dampening the production of pro-inflammatory mediators, as occurs in an influenza-induced lung injury model (27). During severe COVID-19, the heightened levels of IL-1β in several COVID-19 patients (11, 12) indicates the formation of an NLRP3 inflammasome that converts pro-IL-1β to mature IL-1β (54). BTK binds to and phosphorylates NLRP3, thereby promoting its oligomerization and assembly into an inflammasome (24–26). BTK inhibitors such as acalabrutinib inhibit inflammasome-mediated production of IL-1β, as observed in a model of influenza-induced lung injury (27). SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; ACE2, angiotensin-converting enzyme 2; TLR, Toll-like receptor; MyD88, myeloid differentiation primary response 88; BTK, Bruton tyrosine kinase; NF-κB, nuclear factor kappa B; NLRP3, NLR family pyrin domain containing 3; ASC, Apoptosis-associated speck-like protein containing a caspase recruitment domain; ORF3a, open reading frame 3a; IFN-γ, interferon gamma; IL, interleukin; IL-12R, IL-12 receptor; CCL2, C-C motif chemokine ligand 2; CXCL1, C-X-C motif chemokine ligand 1; CXCR2, C-X-C motif chemokine receptor 2.] Based on these considerations, we hypothesized that dysregulated BTK-dependent macrophage signaling is central to the exaggerated inflammatory responses and pulmonary sequelae of infection with SARS-CoV-2 and potentially other single-stranded RNA viruses. In an effort to reduce inflammation and improve clinical outcome of patients with severe COVID-19, we administered acalabrutinib, a highly specific covalent inhibitor of BTK approved in the United States for the treatment of lymphoid malignancies (28). Herein, we present a prospective off-label clinical study of 19 hospitalized patients with COVID-19 and severe hypoxia who also had evidence of inflammation and/or severe lymphopenia. RESULTS Patient Characteristics This prospective off-label clinical study includes 19 hospitalized patients with severe COVID-19 who received off-label acalabrutinib between March 20, 2020 (date of treatment of the first patient) through April 10, 2020 with formal data collection completed on April 23, 2020 (Table S1). Entry criteria for this study were confirmed COVID-19 requiring hospitalization for hypoxemia (room air blood oxygen saturation (SpO2) of 94% or less) and evidence of inflammation (C-reactive protein (CRP) > 10 mg/dL and/or ferritin > 500 ng/mL) and/or lymphopenia (absolute lymphocyte count (ALC) < 1000 cells/μL). Among these patients, 13 (68%) were men and the median age was 61 years with a range of 45 to 84 years (Table 1). Eleven (58%) patients were receiving supplemental oxygen for a median of 2 days (range: 1-12), 7/11 (64%) of whom were on high flow nasal cannula at the time they began acalabrutinib (“supplemental oxygen cohort”). All but one patient had an increasing oxygen demand at the time of treatment initiation. In addition, 8 (42%) patients were receiving invasive mechanical ventilation for a median of 1.5 (range: 1-22) days prior to acalabrutinib administration (“mechanical ventilation cohort”). Coexisting medical conditions included hypertension in 16/19 (84%), obesity (body mass index > 30 kg/m2) in 13/19 (68%), and diabetes mellitus in 7/19 (37%) with a median (range) of 2 (0-5) co-morbid conditions per patient. [Table: Characteristics of the Patients.Obesity is defined as body mass index ≥ 30 kg/m2, morbid obesity is defined as body mass index ≥ 40 kg/m2.] In the supplemental oxygen cohort, concomitant drugs for the treatment of COVID-19 included steroids and/or hydroxychloroquine in 5/11 (45%) patients each, and in the mechanical ventilation cohort, 6/8 (75%) and 3/8 (38%) patients, respectively, received these drugs. No patients received an anti-IL-6 receptor monoclonal antibody or remdesivir. Laboratory evidence of inflammation with elevated CRP and/or ferritin was present in 18/19 (95%) patients with significantly elevated baseline laboratory abnormalities prior to acalabrutinib dosing including elevated CRP (> 10 mg/dL) in 15/19 (79%) patients [median (range) of 18.7 (2-31.5)]; ferritin (> 500 ng/mL) in 16/19 (84%) patients [median (range) 1240 (155-4168)]; fibrinogen (> 400 mg/dl) in 10/10 (100%) patients [median (range) 605 (409- >1000)]; D-dimer (> 0.5 mcg/mL) in 15/17 (88%) patients [median (range) 1.65 (0.48- >20)]; IL-6 (≥ 15 pg/mL) in 9/9 (100%) patients [median (range) 44 (25-89.8)]; and severely decreased ALC (≤

Read the complete text